1 day Ago By ABMN Staff
Shares of MBX Biosciences, Inc. ( NYSE:MBX – Get Free Report ) traded down 6.6% on Friday .
The company traded as low as $16.50 and last traded at $17.04.
74,612 shares changed hands during mid-day trading, a decline of 55% from the average session volume of 165,992 shares. The stock had previously closed at $18.25.
Analysts Set New Price Targets Several brokerages have issued reports on MBX. Jefferies Financial Group initiated coverage on MBX Biosciences in a research note on Tuesday, October 8th. They issued a “buy” rating and a $35.
00 price target on the stock. JPMorgan Chase & Co. started coverage on shares of MBX Biosciences in a research report on Tuesday, October 8th.
They set an “overweight” rating and a $30.00 target price on the stock. Stifel Nicolaus started coverage on shares of MBX Biosciences in a research note on Tuesday, October 8th.
They set a “buy” rating and a $40.00 target price on the stock. Finally, Guggenheim began coverage on shares of MBX Biosciences in a research note on Tuesday, October 8th.
They issued a “buy” rating and a $44.00 price target for the company. View Our Latest Research Report on MBX MBX Biosciences Price Performance MBX Biosciences ( NYSE:MBX – Get Free Report ) last announced its quarterly earnings results on Thursday, November 7th.
The company reported ($2.78) EPS for the quarter, missing analysts’ consensus estimates of ($2.72) by ($0.
06). As a group, equities analysts forecast that MBX Biosciences, Inc. will post -13.
21 earnings per share for the current fiscal year. Institutional Investors Weigh In On MBX Biosciences A number of institutional investors and hedge funds have recently made changes to their positions in MBX. Point72 Asia Singapore Pte.
Ltd. purchased a new stake in shares of MBX Biosciences in the third quarter worth approximately $278,000. Point72 Asset Management L.
P. purchased a new stake in MBX Biosciences in the 3rd quarter valued at $405,000. Barclays PLC bought a new position in MBX Biosciences during the 3rd quarter valued at $426,000.
Geode Capital Management LLC purchased a new position in MBX Biosciences during the 3rd quarter worth $579,000. Finally, Point72 DIFC Ltd purchased a new position in MBX Biosciences during the 3rd quarter worth $624,000. About MBX Biosciences ( Get Free Report ) MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. Read More Receive News & Ratings for MBX Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MBX Biosciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
